World Hungers for Sand while Germany has much of it

This stock photo shows a beach in Monterey, California. (AP)
This stock photo shows a beach in Monterey, California. (AP)
TT

World Hungers for Sand while Germany has much of it

This stock photo shows a beach in Monterey, California. (AP)
This stock photo shows a beach in Monterey, California. (AP)

As incredible as it sounds, the world is running out of sand. Or at least the kind of sand that industries need.

According to the UN Environment Program (UNEP), sand and gravel, known as aggregates, are used in volumes greater than any other raw material on earth except water. And their use greatly exceeds natural renewal rates, the program says.

Kay-Christian Emeis, director of the Institute of Coastal Research at the Helmholtz Center for Materials and Coastal Research (HZG) near Hamburg, Germany, says that worldwide demand for sand is enormous, an estimated 14 billion tons annually, more than half of which is used in Asia.

UNEP explained that sand is indispensable in the industry of many things, such as glass, paper, toothpaste, detergents, cosmetics, electronics and aeronautics, and it is used predominantly in construction and land restorations. Concrete is made with cement, water, sand and gravel.

Even desert countries, like Saudi Arabia and the United Arab Emirates, import sand (marine sand) from Australia, for example to build their skyscrapers.

Harald Elsner, a geologist at Germany's Federal Institute for Geosciences and Natural Resources (BGR) notes that the mineral composition and grain-size distribution of desert sand are not suited to construction.

Most desert sand cannot be used for concrete or land reclamation, as wind erosion shapes round grains that do not blend well, UNEP added.

When Dubai created a group of 300 artificial islands representing a map of the world, it used 450 million tons of Australian sand. As the HZG explains, desert sand would be blown away much too quickly.

The worldwide construction boom, particularly in China, has not left Germany a bystander. According to government statistics, more than 270,000 dwellings in Germany were either newly built or reconstructed in 2016, which is a high record.

This year, the German Construction Industry Federation expects the number to top 300,000.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”